Vaxart Inc. (NB11)
Munich
Closed
Oct 23, 2026
Day's Range
0.320052 wk Range
0.3200Overview - NB11 - Vaxart Inc.
Key Statistics
Valuation
Enterprise Value
-44.82M
P/E (Trailing)
4.57
PEG Ratio
-0.31
Price / Book
0.94
EV / EBITDA
-1.58
Profitability
Operating Margin
8.27%
Return on Assets
8.77%
Return on Equity
18.59%
Ownership
Shares Outstanding
242.83M
Price stats
50-Day Avg
0.3200
200-Day Avg
0.3200
Peers - NB11 - Vaxart Inc.
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- NB11MunichVaxart Inc.+0.00%52-week change4.57P/E (Trailing)—Profit Margin
- 0QFMunichModerna Inc.+88.34%52-week change25.19P/E (Trailing)-141.42%Profit Margin
- 0MEMunichTwist Bioscience Corporation+80.52%52-week change-107.77P/E (Trailing)50.72%Profit Margin
- 2LBMunichIovance Biotherapeutics Inc.+85.65%52-week change-11.96P/E (Trailing)34.27%Profit Margin
- 5JA1MunichSprint Bioscience AB+80.46%52-week change0.31P/E (Trailing)92.17%Profit Margin
- B9B9P0MunichNovabay Pharmaceuticals Inc. R+80.00%52-week change-0.01P/E (Trailing)—Profit Margin
- 42ZMunichRevolution Medicines, Inc.+75.14%52-week change-28.39P/E (Trailing)—Profit Margin
Profile Summary - NB11 - Vaxart Inc.
About
Vaxart Inc. is a biotechnology company specializing in the development of oral recombinant vaccines. Its primary function is to create vaccine candidates that can be administered in tablet form, offering a painless and potentially more accessible alternative to traditional injectable vaccines. This innovation is…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
